Last reviewed · How we verify

AFT Pharmaceuticals, Ltd. — Portfolio Competitive Intelligence Brief

AFT Pharmaceuticals, Ltd. pipeline: 0 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Maxigesic IV Maxigesic IV phase 3 Fixed-dose combination analgesic/NSAID Prostaglandin synthesis inhibitors (COX-1, COX-2, and central pain pathways) Pain Management
Combogesic® tablets Combogesic® tablets phase 3 Fixed-dose combination analgesic/NSAID COX-1, COX-2 (ibuprofen); central pain pathways (paracetamol) Pain Management

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Universidade Estadual de Ponta Grossa · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for AFT Pharmaceuticals, Ltd.:

Cite this brief

Drug Landscape (2026). AFT Pharmaceuticals, Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/aft-pharmaceuticals-ltd. Accessed 2026-06-09.

Related